Takashi Morishita1, Katsumasa Miyaji2, Izumi Akao1, Keiji Fujita1, Hiromi Nakayama1, Kenichi Hisamatsu3, Mitsuru Munemasa3, Yoshihisa Fujimoto3, Hiromi Matsubara3. 1. Division of Clinical Laboratory, National Hospital Organization, Okayama Medical Center, 1711-1 Tamasu, Kita-ku, Okayama, 701-1192, Japan. 2. Division of Cardiology, National Hospital Organization, Okayama Medical Center, 1711-1 Tamasu, Kita-ku, Okayama, 701-1192, Japan. kmiyaji@okayama3.hosp.go.jp. 3. Division of Cardiology, National Hospital Organization, Okayama Medical Center, 1711-1 Tamasu, Kita-ku, Okayama, 701-1192, Japan.
Abstract
PURPOSE: Echocardiography is useful not only for detecting pulmonary hypertension (PH) but also for estimating the severity of PH by evaluating various morphological changes of the heart caused by pressure and volume overload and by ventricular interaction. We investigated whether a novel echocardiographic index, i.e., the ratio of the atrial areas (RA/LA), would be useful for evaluating the clinical status of patients with pulmonary arterial hypertension (PAH) treated with intravenous epoprostenol. METHODS: We introduced epoprostenol therapy for seven PAH patients without severe tricuspid regurgitation. We evaluated clinical criteria indicative of prognosis, for example World Health Organization functional class (WHO-FC), brain natriuretic peptide (BNP) level, echocardiographic indices such as indexed RA area and RA/LA, and hemodynamics before and one year after intravenous epoprostenol therapy. RESULTS: There were significant improvements in both RA/LA (2.5 ± 1.0, 1.3 ± 0.4, P < 0.001) and indexed RA area (22.5 ± 8.9, 14.5 ± 5.8, P < 0.001). The improvement in RA/LA was more sensitive than that in indexed RA area (P < 0.01). Moreover, RA/LA was significantly correlated with WHO-FC (r = 0.50, P < 0.01) and BNP level (r = 0.82, P < 0.01). CONCLUSIONS: RA/LA is useful for evaluating the clinical status of patients with PAH treated with intravenous epoprostenol.
PURPOSE: Echocardiography is useful not only for detecting pulmonary hypertension (PH) but also for estimating the severity of PH by evaluating various morphological changes of the heart caused by pressure and volume overload and by ventricular interaction. We investigated whether a novel echocardiographic index, i.e., the ratio of the atrial areas (RA/LA), would be useful for evaluating the clinical status of patients with pulmonary arterial hypertension (PAH) treated with intravenous epoprostenol. METHODS: We introduced epoprostenol therapy for seven PAH patients without severe tricuspid regurgitation. We evaluated clinical criteria indicative of prognosis, for example World Health Organization functional class (WHO-FC), brain natriuretic peptide (BNP) level, echocardiographic indices such as indexed RA area and RA/LA, and hemodynamics before and one year after intravenous epoprostenol therapy. RESULTS: There were significant improvements in both RA/LA (2.5 ± 1.0, 1.3 ± 0.4, P < 0.001) and indexed RA area (22.5 ± 8.9, 14.5 ± 5.8, P < 0.001). The improvement in RA/LA was more sensitive than that in indexed RA area (P < 0.01). Moreover, RA/LA was significantly correlated with WHO-FC (r = 0.50, P < 0.01) and BNP level (r = 0.82, P < 0.01). CONCLUSIONS:RA/LA is useful for evaluating the clinical status of patients with PAH treated with intravenous epoprostenol.
Entities:
Keywords:
Echocardiography; Pulmonary arterial hypertension; Ratio of the atrial areas
Authors: E Bossone; T H Duong-Wagner; G Paciocco; H Oral; M Ricciardi; D S Bach; M Rubenfire; W F Armstrong Journal: J Am Soc Echocardiogr Date: 1999-08 Impact factor: 5.251
Authors: N Nagaya; T Nishikimi; M Uematsu; T Satoh; S Kyotani; F Sakamaki; M Kakishita; K Fukushima; Y Okano; N Nakanishi; K Miyatake; K Kangawa Journal: Circulation Date: 2000-08-22 Impact factor: 29.690
Authors: Ronald J Raymond; Alan L Hinderliter; Park W Willis; David Ralph; Edgar J Caldwell; William Williams; Neil A Ettinger; Nicholas S Hill; Warren R Summer; Bennett de Boisblanc; Todd Schwartz; Gary Koch; Linda M Clayton; Maria M Jöbsis; James W Crow; Walker Long Journal: J Am Coll Cardiol Date: 2002-04-03 Impact factor: 24.094
Authors: A L Hinderliter; P W Willis; W Long; W R Clarke; D Ralph; E J Caldwell; W Williams; N A Ettinger; N S Hill; W R Summer; B de Biosblanc; G Koch; S Li; L M Clayton; M M Jöbsis; J W Crow Journal: Am J Cardiol Date: 1999-08-15 Impact factor: 2.778
Authors: A L Hinderliter; P W Willis; R J Barst; S Rich; L J Rubin; D B Badesch; B M Groves; M D McGoon; V F Tapson; R C Bourge; B H Brundage; S K Koerner; D Langleben; C A Keller; S Murali; B F Uretsky; G Koch; S Li; L M Clayton; M M Jöbsis; S D Blackburn; J W Crow; W A Long Journal: Circulation Date: 1997-03-18 Impact factor: 29.690
Authors: Hanno H Leuchte; Michael Holzapfel; Rainer A Baumgartner; Isabelle Ding; Claus Neurohr; Michael Vogeser; Tilman Kolbe; Martin Schwaiblmair; Jürgen Behr Journal: J Am Coll Cardiol Date: 2004-03-03 Impact factor: 24.094